Cambridge Investment Research Advisors
VKTX icon

Cambridge Investment Research Advisors’s Viking Therapeutics VKTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Buy
11,191
+388
+4% +$12.5K ﹤0.01% 3092
2026
Q1 		$352K Sell
10,803
-340
-3% -$10.9K ﹤0.01% 3137
2025
Q4 		$392K Sell
11,143
-1,473
-12% -$52.2K ﹤0.01% 2947
2025
Q3 		$332K Sell
12,616
-950
-7% -$28.3K ﹤0.01% 3027
2025
Q2 		$359K Sell
13,566
-16,155
-54% -$425K ﹤0.01% 2834
2025
Q1 		$718K Buy
29,721
+16,302
+121% +$515K ﹤0.01% 2141
2024
Q4 		$540K Sell
13,419
-28,970
-68% -$1.65M ﹤0.01% 2367
2024
Q3 		$2.68M Buy
42,389
+17,261
+69% +$1.01M 0.01% 1147
2024
Q2 		$1.33M Buy
25,128
+10,447
+71% +$685K ﹤0.01% 1573
2024
Q1 		$1.2M Buy
+14,681
New +$653K ﹤0.01% 1605
2023
Q3 		– Sell
-13,741
Closed -$223K – 3270
2023
Q2 		$223K Buy
+13,741
New +$288K ﹤0.01% 2788
2023
Q1 		– Sell
-10,113
Closed -$95K – 3261
2022
Q4 		$95K Sell
10,113
-701
-6% -$3.13K ﹤0.01% 2920
2022
Q3 		$29K Sell
10,814
-499
-4% -$1.63K ﹤0.01% 2984
2022
Q2 		$33K Hold
11,313
– – ﹤0.01% 2973
2022
Q1 		$34K Hold
11,313
– – ﹤0.01% 3101
2021
Q4 		$52K Buy
11,313
+200
+2% +$1.12K ﹤0.01% 3100
2021
Q3 		$70K Buy
11,113
+185
+2% +$1.14K ﹤0.01% 3001
2021
Q2 		$65K Sell
10,928
-3,135
-22% -$18.6K ﹤0.01% 3012
2021
Q1 		$89K Buy
+14,063
New +$98.9K ﹤0.01% 2772
2019
Q2 		– Sell
-14,275
Closed -$142K – 2361
2019
Q1 		$142K Buy
+14,275
New +$119K ﹤0.01% 2144

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Cambridge Investment Research Advisors's VKTX Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Viking Therapeutics (VKTX) stake by 3.6% in Q2 2026, buying an estimated $12.5K and bringing the position to 11,191 shares worth $437K. The position accounts for ﹤0.01% of the portfolio, ranked #3092.

Cambridge Investment Research Advisors first reported a position in VKTX in Q1 2019 and has held it in 20 quarters since. The position peaked at $2.68M in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Cambridge Investment Research Advisors held 11,191 shares of Viking Therapeutics worth $437K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 388 Viking Therapeutics shares in Q2 2026, an estimated $12.5K.
  • Viking Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3092 holding.
  • Cambridge Investment Research Advisors first reported a position in Viking Therapeutics in Q1 2019 and has held it in 20 quarters since.
  • Cambridge Investment Research Advisors's Viking Therapeutics position peaked at $2.68M in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.